ICT-121 is an immunotherapy that targets cancer stem cells
ImmunoCellular Therapeutics, Ltd. announced on June 18th 2009, about the filing of the U.S. patient application relating to its novel vaccine technology ICT-121 targeting cancer stem cells.
ICT-121 is IMUC’s cancer stem cell (CSC) vaccine product candidate that consists of a peptide to stimulate a cytotoxic T-lymphocyte (CTL) response to CD133, which is generally overexpressed on the CSCs.
IMUC is looking forward to evaluate ICT-121 in a Phase I clinical study for glioblastoma within the third quarter of this year.
Many cancer therapies are limited by their ability to be used only in patients with certain human leukocyte antigen (HLA) types. Identification of the new peptides for use in IMUC’s vaccine should enable the use of IMUC’s product candidate in patients with many different HLA types. The Company currently has 25 issued or pending patents.
According to Manish Singh, Ph.D., IMUC’s president and chief executive officer,
ICT-121 is an immunotherapy that targets cancer stem cells - a very exciting approach given the product’s mission of destroying cancer cells at their root as well as its proven ability in preclinical studies to be highly targeted for destroying cancer cells.
This product may have applicability to multiple types of cancer, but our first clinical target will be glioblastoma.